Feedback / Questions
osemitamab (TST001) - Transcenta
https://www.globenewswire.com/news-release/2025/12/05/3200420/0/en/Transcenta-Therapeutics-Presents-Updated-Efficacy-Data-from-the-Phase-I-II-Transtar102-Trial-of-Osemitamab-plus-Nivolumab-and-CAPOX-in-First-Line-G-GEJ-Cancer-at-ESMO-Asia.html
Dec 4, 2025
SHARE THIS
Print
Email
More sharing
Reddit
StumbleUpon
Delicious
Next